Krebs Biochemicals & Industries Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Operating margins have improved to -34.7% from -55.0%
- Working capital cycle has improved - days down from -321 to -786
CONS
- Net worth is negative - accumulated losses have eroded equity
- Company is loss-making at the operating / net level
- Operating cash flow has been negative in recent years
- Company has a low return on capital employed of -25.8%
- Company has a low return on equity of 0.0% over last 3 years
- Interest coverage is weak at -3.6x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| KREBSBIO | 58.77 | 0.00 | 126.71 | 0.00 | -2.49 | 53.29 | 6.98 | 27.45 | -29.92 | 11.84 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 | 15 | 13 | 12 | 13 | 13 | 11 | 6 | 5 | 4 | 7 | 7 | 7 | |
| 13 | 16 | 15 | 15 | 15 | 16 | 16 | 12 | 8 | 7 | 7 | 8 | 10 | |
| Operating Profit | -3 | -1 | -2 | -3 | -2 | -3 | -5 | -5 | -2 | -3 | 0 | -1 | -3 |
| OPM % | -24.76% | -6.04% | -16.10% | -26.07% | -17.07% | -21.07% | -41.06% | -88.69% | -38.14% | -66.91% | 3.99% | -12.78% | -37.82% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before Tax | -5 | -4 | -5 | -6 | -5 | -6 | -8 | -8 | -5 | -6 | -3 | -2 | -2 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.24% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | -5 | -4 | -5 | -6 | -5 | -6 | -8 | -8 | -5 | -6 | -3 | -2 | -2 |
| -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.83 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 25 | |
| 14 | 12 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 31 | |
| Operating Profit | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -6 |
| OPM % | -961.72% | -226.62% | -22.21% | -20.44% | -55.53% | -32.73% | -56.94% | -30.27% | -17.30% | -34.70% | -23.82% |
| 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | |
| Interest | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 6 |
| Profit before Tax | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -14 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.06% | -0.00% |
| Net Profit | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -14 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.37 | -20.81 | -11.30 | -9.15 | -12.49 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 5%
- 3 Years:
- -10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- -5%
- 5 Years:
- -17%
- 3 Years:
- -3%
- 1 Year:
- -24%
RETURN ON EQUITY
- 10 Years:
- -98%
- 5 Years:
- 0%
- 3 Years:
- 0%
- Last Year:
- 0%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 |
| -4 | -12 | -32 | -31 | -51 | -67 | -97 | -121 | -141 | -168 | |
| 74 | 90 | 101 | 100 | 113 | 161 | 194 | 233 | 242 | 260 | |
| Trade Payables | 12 | 11 | 18 | 21 | 23 | 21 | 38 | 15 | 19 | 18 |
| 20 | 20 | 25 | 36 | 31 | 24 | 33 | 26 | 36 | 37 | |
| Total Liabilities | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
| 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | |
| Capital Work in Progress | 11 | 4 | 2 | 2 | 2 | 10 | 7 | 2 | 0 | 1 |
| 6 | 5 | 12 | 9 | 15 | 17 | 26 | 12 | 10 | 6 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | |
| Cash & Bank | 0 | 0 | 0 | 17 | 0 | 1 | 0 | 0 | 0 | 0 |
| 7 | 11 | 11 | 13 | 11 | 14 | 19 | 13 | 16 | 16 | |
| Total Assets | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -15 | -8 | -1 | 4 | -35 | -15 | -17 | -25 | 2 | -8 | |
| Cash from Investing | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 | -5 |
| Cash from Financing | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 |
| -6 | -0 | 0 | 17 | -17 | 1 | -1 | -0 | 0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Krebs Biochemicals and Industries Limited has informed the Exchange regarding 'Machine Readable financial results for the quarter ended 30.06.2026.'.
2026-09-07 - Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
2026-09-04 - Krebs Biochemicals and Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026
2026-09-03 - Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. prior intimation of 34th AGM of the Company.
2026-08-07 - Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-06 - Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-02 - Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
2026-06-26 - Krebs Biochemicals and Industries Limited has informed the Exchange about Scheme of Arrangement
2026-06-26 - Outcome of Board MEETING
News
Recent coverage and analyst commentary for KREBSBIO
Loading news…
AI Stock Analyst
Krebs Biochemicals & Industries Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account